US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Generate Biomedicines, Inc. - Common Stock
(NQ:
GENB
)
13.80
-0.11 (-0.79%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Generate Biomedicines, Inc. - Common Stock
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
↗
August 05, 2026
Generate Biomedicines focuses on AI-enabled drug discovery.
Via
The Motley Fool
Topics
Artificial Intelligence
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
↗
July 11, 2026
One small investment offers big benefits for Nvidia.
Via
The Motley Fool
Topics
Artificial Intelligence
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
↗
July 07, 2026
Ark Invest's top investor is adding to stocks that went public over the past year.
Via
The Motley Fool
Topics
ETFs
Initial Public Offering
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
↗
June 27, 2026
Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting.
Via
The Motley Fool
Topics
Artificial Intelligence
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
↗
May 31, 2026
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Via
The Motley Fool
Topics
Initial Public Offering
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
↗
May 19, 2026
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Regulatory Compliance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
March 03, 2026
The growth investor kicked off this week by buying up some hard-hit stocks.
Via
The Motley Fool
